The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of lung transplant recipients (D+/R-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease."
Adults over 18 years old
Lung transplant recipients (D+/R-) pre-transplant.
Having an undetectable CMV polymerase chain reaction assay (PCR) within the 96 hours prior to the start of letermovir prophylaxis.
Patients who have provided written informed consent.
HIV-infected patients.
Patients with multivisceral transplant.
Patients unable to comply with the follow-up protocol.
Receiving a different antiviral prophylaxis other than ganciclovir prior to letermovir prophylaxis.
Maimónides Biomedical Research Institute of Córdoba
Lead sponsor
MERCK SHARP & DOHME DE ESPAÑA S.A.
Collaborator